On Wednesday Peel Hunt retained its broker consensus on shares of Cello Group PLC (LON:CLL) giving the company a ‘Buy’ rating.
Peel Hunt gave shares of Cello Group PLC a price target of 130 indicating a potential increase of 26.21% from Cello Group PLC’s current price of 103.
In the prior 12 months Cello Group PLC’s stock price has increased by 29.27% from 79.68 to 103.
Cello Group PLC has 86,809,000 shares in issue which have a share price of 103 giving Cello Group PLC a market capitalisation of 89.41M GBp .
The 52 week high of Cello Group PLC’s shares is 115 whilst the 52 week low for the company’s shares is 77.1. The 50 day moving average of LON:CLL is 106.32 and the 200 day moving average is 99.64.
Cello Group plc is a United Kingdom-based healthcare and consumer strategic marketing company. The Company is engaged in providing market research, consulting and direct marketing services. The Company operates through two segments: Cello Health and Cello Signal. The Cello Health Division provides market research, consulting and communications services principally to the Company’s pharmaceutical and healthcare clients. The Cello Signal Division provides market research and direct communications services principally to the Company’s consumer facing clients. The Company delivers its services from office networks in the United Kingdom, the United States, Singapore and Hong Kong. The Company’s subsidiaries include 2CV Limited, Cello Group Inc, Farm Communications Limited, Market Research International Limited and Insight Medical Research Limited.